IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

類似資料

• Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
  著者:: Pardanani, A, 等
  出版事項: (2013)
• WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
  著者:: Patnaik, M M, 等
  出版事項: (2010)
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
  著者:: Tefferi, A, 等
  出版事項: (2010)
• Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
  著者:: Vallapureddy, Rangit R., 等
  出版事項: (2019)
• Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
  著者:: Patnaik, Mrinal M., 等
  出版事項: (2019)